IRONWOOD PHARMACEUTICALS, INC. Cost of Revenue
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Cost of Revenue of $19.10 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2018-02-22
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2017-12-31 was $8.98M.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2017-09-30 was $6.08M.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2017-06-30 was $3.50M.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2017-03-31 was $531.00K.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for fiscal 2017 was $19.10M, a 922.32% increase from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for fiscal 2016 was $1.87M, a 15466.67% increase from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for fiscal 2015 was $12.00K, a 99.77% decline from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. cost of revenue for fiscal 2014 was $5.29M, a 26.54% decline from fiscal 2013.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|
| 2017-12-31 | $8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $15.06M derived: sum of 2 quarters · filed 2018-02-22 | $18.57M derived: sum of 3 quarters · filed 2018-02-22 | $19.10M 10-K · filed 2018-02-22 | ||
| 2017-09-30 | $6.08M 10-Q · filed 2017-11-02 | $9.58M derived: sum of 2 quarters · filed 2017-11-02 | $10.11M 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | $3.50M 10-Q · filed 2017-08-03 | $4.03M 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | $531.00K 10-Q · filed 2017-05-08 | |||||
| 2016-12-31 | $1.87M 10-K · filed 2018-02-22 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$8.15M derived: sum of 2 quarters · filed 2018-02-22 | $0.00 derived: sum of 3 quarters · filed 2018-02-22 | $12.00K 10-K · filed 2018-02-22 | ||
| 2015-09-30 | -$8.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $12.00K 10-Q · filed 2015-11-05 | $1.75M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $8.15M 10-Q · filed 2015-08-07 | $8.16M 10-Q · filed 2015-08-07 | $9.90M derived: sum of 3 quarters · filed 2017-02-22 | $1.01M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-03-31 | $12.00K 10-Q · filed 2016-05-10 | $1.75M derived: sum of 2 quarters · filed 2017-02-22 | -$7.14M derived: sum of 3 quarters · filed 2017-02-22 | $3.38M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2014-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | -$7.15M derived: sum of 2 quarters · filed 2017-02-22 | $3.37M derived: sum of 3 quarters · filed 2017-02-22 | $5.29M 10-K · filed 2017-02-22 | $25.58M 10-K · filed 2015-02-18 | |
| 2014-09-30 | -$8.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.62M derived: sum of 2 quarters · filed 2015-11-05 | $3.55M 10-Q · filed 2015-11-05 | $12.44M 10-Q · filed 2014-11-05 | $4.08M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $10.52M 10-Q · filed 2015-08-07 | $12.44M 10-Q · filed 2015-08-07 | $12.97M derived: sum of 3 quarters · filed 2016-02-19 | $15.00M derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-03-31 | $1.92M 10-Q · filed 2015-05-06 | $2.46M derived: sum of 2 quarters · filed 2016-02-19 | $4.48M derived: sum of 3 quarters · filed 2016-02-19 | $7.90M derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2013-12-31 | $533.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $2.55M derived: sum of 2 quarters · filed 2016-02-19 | $5.97M derived: sum of 3 quarters · filed 2016-02-19 | $7.20M 10-K · filed 2016-02-19 | ||
| 2013-09-30 | $2.02M 10-Q · filed 2014-11-05 | $5.44M derived: sum of 2 quarters · filed 2014-11-05 | $6.67M 10-Q · filed 2014-11-05 | |||
| 2013-06-30 | $3.42M 10-Q · filed 2014-08-05 | $4.65M 10-Q · filed 2014-08-05 | ||||
| 2013-03-31 | $1.23M 10-Q · filed 2014-04-29 | |||||
| 2012-12-31 | $965.00K 10-K · filed 2015-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |